Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Columbia scientists develop cancer terminator viruses

20.09.2005


Results advance quest for viral-based therapies for cancer



Researchers at Columbia University Medical Center continue to make strides in their work to develop the next generation of effective viral-based therapies for cancer. Two papers about promising research with genetically engineered viruses studied in mice, published today in the journals Cancer Research and the Proceedings of the National Academy of Sciences (PNAS), bring us significantly closer to this objective and the start of clinical trials with these viral-based therapies in cancer patients.

Both papers were led by Paul B. Fisher, M.Ph., Ph.D., professor of clinical pathology and the Michael and Stella Chernow Urological Cancer Research Scientist at Columbia University College of Physicians and Surgeons.


In the Cancer Research paper, the researchers discuss the development of a "terminator" virus, which was administered to mice with pancreatic cancers at both primary and distant sites (akin to metastases). As predicted, when the virus was injected directly into the primary tumor, the virus destroyed not only the primary tumor, but also distant tumors. While the infection caused by the virus was sufficient to kill the primary tumor, a second weapon added to the virus ¡V interferon-gamma (IFN-ƒ×) ¡V eliminated the metastases. IFN-ƒ× elicited an anti-tumor immune response against the distant metastatic cancer cells.

In the PNAS paper, Dr. Fisher and the team describe the production of a virus conceptually similar to the "terminator" virus, which selectively replicates and kills breast cancer cells in mice. Human breast tumor xenografts were established on both sides of immune-deficient mice. Results found that treating the tumors on just one side of the animal with very few injections of this modified virus not only cured the injected tumors, but also resulted in the destruction of the tumors on the opposite side of the animal. Instead of carrying IFN-ƒ× as the other virus did, this virus carried a gene called mda-7/IL-24, a novel gene identified and cloned in Dr. Fisher’s laboratory, which is selectively toxic to cancer cells and is now in phase II clinical trials as a cancer gene therapeutic.

"We are extremely excited about these results and the prospect of one day using a form of the cancer terminator virus in human clinical trials," said Dr. Fisher, the study’s senior author. "While the results of these trials need to be investigated further and replicated in future trials, we believe that viral-based therapies will someday soon be a standard part of the cancer armamentarium."

About the "Terminator" Viruses

The "terminator" viruses have the potential to become effective treatments for a wide range of tumors - such as ovarian, pancreatic, breast, brain (glioma), prostate, skin (melanoma) and colon cancer - because the virus is constructed to exploit a characteristic of all solid cancers. However, clinical trials are necessary before such treatments can be approved by the U.S. Food and Drug Administration and available for patients.

These publications are a continuation of research published in the Jan. 25, 2005 issue of PNAS, where the same research team, also led by Dr. Fisher, incorporated gene therapy into a specially designed non-replicating virus to overcome one of the major hurdles of gene therapy: its tendency to kill normal cells in the process of eradicating cancer cells. The virus eradicated prostate cancer cells in the lab and in animals, while leaving normal cells unscathed.

The present cancer "terminator" viruses represent the next generation of therapeutic viruses that permit replication uniquely in cancer cells with simultaneous production of immune modulating and toxic genes. These viruses effectively eliminate primary tumors and distant tumors (metastases) without harming normal cells or tissues.

Dr. Fisher’s cancer research team includes Columbia University Medical Center investigators: Drs. Zao-zhong Su (research scientist), Devanand Sarkar (associate research scientist), Nicolaq Vozhilla (pathology technician), Eun Sook Park (pathology technician) and Pankaj Gupta (associate research scientist). Two scientists from Virginia Commonwealth University in Richmond, Va. are also involved in the research: Mr. Aaron Randolph (graduate student) and Dr. Kristoffer Valerie (professor).

Elizabeth Streich | EurekAlert!
Further information:
http://www.columbia.edu

More articles from Life Sciences:

nachricht A Map of the Cell’s Power Station
18.08.2017 | Albert-Ludwigs-Universität Freiburg im Breisgau

nachricht On the way to developing a new active ingredient against chronic infections
21.08.2017 | Deutsches Zentrum für Infektionsforschung

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

Nagoya physicists resolve long-standing mystery of structure-less transition

21.08.2017 | Materials Sciences

Chronic stress induces fatal organ dysfunctions via a new neural circuit

21.08.2017 | Health and Medicine

Scientists from the MSU studied new liquid-crystalline photochrom

21.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>